MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment.
Key Highlights
-
U.S. Provisional Patents filed expanding HT-001’s therapeutic reach.
-
Indications covered:
-
MENIN inhibitors are an emerging oncology class with significant promise in acute leukemias and select solid tumors, but treatment-limiting rashes remain a major clinical challenge.
-
HT-001 designed to improve tolerability of cancer therapies by addressing dermatological side effects, potentially enabling patients to remain on therapy longer.
NEW YORK, Sept. 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation treatments for dermatological and inflammatory conditions, today announced the expansion of its intellectual property portfolio for HT-001, its lead topical therapeutic candidate. The Company has filed multiple U.S. Provisional Patent Applications covering novel dermatological indications, broadening the commercial and clinical potential of HT-001.
The filings include:
-
Treatment of Drug-Induced Hypersensitivity Syndrome
-
Treatment of Radiotherapy-Induced Rash
-
Treatment of Dermatological Conditions Associated with MENIN Inhibitor Therapy
“These additional patent applications demonstrate our commitment to unlocking the full therapeutic potential of HT-001 across multiple high-value indications,” said Robb Knie, Chief Executive Officer of Hoth Therapeutics. “Drug-induced hypersensitivity, radiotherapy-related rash, and MENIN inhibitor-associated dermatological conditions represent areas of significant unmet need. Expanding our IP protection into these indications strategically positions Hoth to address major markets in oncology supportive care and beyond.”
MENIN Inhibitor Therapy and the Role of HT-001
MENIN inhibitors are an emerging class of targeted oncology drugs designed to block the interaction between the menin protein and MLL1/KMT2A fusion proteins — genetic drivers implicated in acute leukemias and other cancers. Early clinical data from leading oncology companies have shown that MENIN inhibitors can induce strong antitumor activity, making them one of the most closely watched new therapeutic classes in cancer drug development.
However, patients receiving MENIN inhibitors frequently experience significant dermatological side effects, including painful or disfiguring rashes that can lead to dose reductions or treatment discontinuation. These adverse events may limit the full therapeutic potential of MENIN inhibitor therapy.
HT-001’s novel topical formulation is designed to address these dermatological toxicities directly, offering patients relief from rash and skin irritation without interrupting or reducing their cancer treatment. By improving tolerability, HT-001 could help patients stay on therapy longer and maximize the clinical benefit of MENIN inhibitors.
Expanding the Potential of HT-001
HT-001 is currently being advanced as a topical therapeutic for chemotherapy-induced rash, a dose-limiting side effect affecting patients receiving EGFR inhibitors and other targeted therapies. The patent filings broaden the potential utility of HT-001 to additional drug-induced and treatment-related skin disorders, further establishing the program as a versatile platform candidate.
“With this expanded IP portfolio, HT-001 is positioned not only as a targeted solution for oncology-related rash but also as a potential cornerstone therapy for a range of dermatological conditions driven by emerging cancer treatments,” added Knie. “This expansion underscores our strategy to build durable value through innovation, intellectual property, and pipeline diversification.”
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .